Jason Hope Helps Students With Great Ideas

A native of Arizona, Jason Hope grew up in Tempe and later attended college at Arizona State University. He earned an MBA from the school’s W.P. Carey School of Business and has since made an impact in the state and on the world. He’s a business owner, a futurist, an entrepreneur, and a philanthropist who is going places in the world.

Jason Hope is a name that business professionals know and trust. He’s been on the scene for some time now, bringing his passion and understanding of technology full throttle in his many published articles and blogs. He’s a futurist who serves on the Internet of Things council and who offers a plethora of other services and benefits to the world. Most importantly, the entrepreneur believes in the power of the IoT and the future of technology.

When Jason Hope peaks, he does so with a positivity and certainty in his voice that causes people to listen with interest to what he says. He has insight and advice that helps modern businesses achieve success and has a philanthropist heart that reaches out to those whom he believes can better the world in some way. He proves this with his Angel Investment Money for high school and college students. Although not every student who requests an investment receives funds, Jason Hope chooses those he feels most worthy and offers a helping hand.

As someone who’s faced the triumphs of opening a business firsthand, Jason Hope decided to offer Angel Investments of $5,000 to $500,000 to high school and college students whose ideas would better the world. It’s hard to save enough money to start a business, especially if you’re a young person. But, since a young mind has the most amazing ideas, he reaches out to help. The Angel Investments helps many students each year.

Learn more about Jason Hope: http://bitsylink.com/2018/07/02/scottsdale-philanthropist-jason-hope-helps-pioneering-nonprofit-fight-aging/

Scott Rocklage Leads The Way By Investing In Expansion Therapeutics

Expansion Therapeutics is a biotech startup based in San Diego, California. It recently held its Series A financing round in which it raised $55.3 million from six venture investment firms. The goal of this company is to provide treatments for genetic disorders. The first disorder it is developing a drug for is myotonic dystrophy type 1, or DM1. DM1 has been shown to be the main cause of adults developing muscular dystrophy.

The four main venture investment firms to have invested in Expansion Therapeutics during this round were Kleiner Perkins, Novartis Venture Fund, 5AM Ventures, and Sanofi Ventures. Two other companies participated to a lesser extent which were Alexandria Venture Investments and RA Capital Management.

RNAs (ribonucleic acid) are molecules which exist in all living cells. Their purpose is to carry instructions from DNA which leads to the synthesis of proteins. In certain people the amount of RNAs can reach a toxic level and this results in DM1 occurring. Once this happens ths person’s heart, muscles, and bodily systems start to become defective and they develop muscular dystrophy.

DM1 can be passed down generation to generation with each subsequent generation having worse symptoms. There has yet to be any good treatment for those who have DM1. Expansion Therapeutics is looking to address this and treat illnesses where too much RNA is created. Their work is a continuation of the research that was developed in the lab of Matthew Disney, Ph.D.

At 5AM Ventures, Scott Rocklage, Ph.D. is the managing partner. He has been a venture investor for the past 15 years. Prior to that he was an executive in the pharmaceutical industry for several years. He started out in the healthcare industry as a researcher and developer. He earned his Ph.D. at the Massachusetts Institute of Technology and continues to live in the greater Boston, MA region.

In addition to investing in healthcare firms, Scott Rocklage is also the chairman of the board for three different firms which are Novira, Relypsa, and Achaogen. He has been on other companies boards in the past like Variation Biotechnologies, Inc. and Epirus Biopharmaceuticals. Learn more: https://www.twst.com/bio/scott-m-rocklage/